Table 1.
Participant characteristics
| Characteristic | Value |
|---|---|
| Age | |
| Years, mean (s.d.) | 48 (15.5) |
| Years, range | 23–75 |
| Gender, women: % (n) | 50 (10) |
| Ethnicity, % (n) | |
| White British | 80 (16) |
| Black British | 5 (1) |
| Mixed ethnicity | 15 (3) |
| Occupation, % (n) | |
| Unemployed | 55 (11) |
| Self-employed | 5 (1) |
| Retired | 20 (4) |
| Volunteer | 5 (1) |
| Student | 5 (1) |
| Living arrangements, % (n) | |
| Supported accommodation | 25 (5) |
| Rehabilitation unit | 5 (1) |
| Alone | 40 (8) |
| With family | 25 (5) |
| With carer | 5 (1) |
| Suicidal experiences, % (n) | |
| Lifetime | 100 (20) |
| Current (at the time of interview) | 20 (4) |
| Duration of illnessa | |
| Years, mean (s.d.) | 22.2 (13.2) |
| Years, range | 0.4–43 |
| Current diagnosis, % (n) | |
| Schizophrenia | 25 (5) |
| Paranoid schizophrenia | 40 (8) |
| Chronic schizophrenia | 5 (1) |
| Treatment resistant schizophrenia | 5 (1) |
| Schizoaffective disorder | 10 (2) |
| Psychotic disorder | 5 (1) |
| Acute psychosis | 5 (1) |
| Unspecified non-organic psychosis | 5 (1) |
| Medication,b % (n) | |
| Clozapine | 25 (5) |
| Aripiprazole | 40 (8) |
| Quetiapine | 5 (1) |
| Olanzapine | 10 (2) |
| Zuclopenthixol | 10 (2) |
| Flupentixol | 10 (2) |
| Risperidone | 5 (1) |
| Fluphenazine | 5 (1) |
| Amisulpride | 5 (1) |
a.
Based on data from 19 participants.
b.
Some participants were prescribed two types of antipsychotic medication.